Literature DB >> 6506393

Primary transitional cell carcinoma of prostate.

G S Nicolaisen, R D Williams.   

Abstract

Primary transitional cell carcinoma of the prostate (TCC-P) is a rare tumor for which definitive therapy remains undefined. To establish a basis for therapy, we analyzed 3 new cases and reviewed the literature. The following points were observed: (1) the true diagnosis is often missed at initial pathologic examination; (2) the tumor has a propensity for extensive local invasion; and (3) it commonly presents with obstructive symptoms in relatively young patients. Treatment recommendations based on our review include: maintenance of a high index of suspicion, especially for fifty to sixty-year-old men with prostate tumors or for suspected prostatic adenocarcinoma that is rapidly progressive and/or unresponsive to hormonal therapy; preoperative pelvic irradiation followed by radical cystoprostatourethrectomy is the treatment of choice in low-stage disease, and combined radiation therapy and chemotherapy should be used for disease beyond the prostate.

Entities:  

Mesh:

Year:  1984        PMID: 6506393     DOI: 10.1016/0090-4295(84)90098-0

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  3 in total

1.  Case report--Cutaneous metastasis from a primary transitional cell carcinoma of prostate.

Authors:  V C Mishra; S F Tindall
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder.

Authors:  Tsutomu Hamasaki; Yukihiro Kondo; Yoshihiko Ogata; Kazuhiro Yoshida; Go Kimura; Hiroyuki Shimizu; Taiji Nishimura
Journal:  Int J Clin Oncol       Date:  2010-01-20       Impact factor: 3.402

3.  Primary urothelial carcinoma of the prostate: A rare case report.

Authors:  Jun Zhou; Cheng Yang; Zhaoxiang Lu; Li Zhang; Yu Yin; Sheng Tai; Chaozhao Liang
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.